Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities

Table 1 Characteristics of patients with nonalcoholic fatty liver disease

Patients (n)	191
Age (years old)	62 (20-90)
Men (%)	81 (42.4)
diabetes (%)	75 (39.3)
HCC	17
EGV	16
Both HCC and EGV	9
AST (U/L)	36 (13-208)
ALT (U/L)	40 (10-214)
Platelet count (×109/L)	207 (45-445)

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; EGV: Esophagogastric varices; HCC: Hepatocellular carcinoma.

Table 2 Sensitivity, specificity, positive predictive value, and negative predictive value of each score and marker (L vs I-H)

	FIB-4		FAST		Agile 3+		Agile 4		LSM		M2BPGi
Risk	L	I-H	L	I-H	L	I-H	L	I-H	L	I-H	L	I-H
n	71	120	87	104	96	95	131	60	73	118	102	89
HCC	0	26	10	16	0	26	7	19	4	22	5	21
P value	< 0.01		0.44		< 0.01		< 0.01		< 0.01		< 0.01
Sensitivity		1		0.62		1		0.73		0.85		0.81
Specificity		0.43		0.53		0.58		0.79		0.44		0.62
PPV		0.22		0.17		0.27		0.36		0.19		0.25
NPV		1		0.90		1		0.95		0.95		0.95
EGV	0	25	6	19	0	25	1	24	0	25	1	24
P value	< 0.01		0.02		< 0.01		< 0.01		< 0.01		< 0.01
Sensitivity		1		0.76		1		0.96		1		0.96
Specificity		0.43		0.52		0.58		0.79		0.44		0.61
PPV		0.21		0.19		0.26		0.41		0.21		0.27
NPV		1		0.94		1		0.99		1		0.99

L: Low-risk; I: Intermediate-risk; H: High-risk; HCC: Hepatocellular carcinoma; EGV: Esophagogastric varix; HCC: Hepatocellular carcinoma; EGV: Esophagogastric varices; PPV: Positive predictive value, NPV: Negative predictive value; M2BPGi: Mac2-binding protein glycosylation isomer; FAST: FibroScan-AST; FIB-4: Fibrosis-4; LSM: Liver stiffness measurement.

Table 3 Sensitivity, specificity, positive predictive value, and negative predictive value of each score and marker (L-I vs H)

	FIB-4		FAST		Agile 3+		Agile 4		LSM		M2BPGi
Risk	L-I	H	L-I	H	L-I	H	L-I	H	L-I	H	L-I	H
n	122	69	146	45	111	80	148	43	136	55	148	43
HCC	3	23	18	8	0	26	12	14	10	16	11	15
P value	< 0.01		0.35		< 0.01		< 0.01		< 0.01		< 0.01
Sensitivity		0.89		0.31		1		0.54		0.62		0.58
Specificity		0.74		0.89		0.67		0.90		0.82		0.90
PPV		0.35		0.30		0.33		0.45		0.36		0.47
NPV		0.98		0.89		1		0.93		0.93		0.93
EGV	2	23	14	11	0	25	2	23	3	22	4	21
P value	< 0.01		0.01		< 0.01		< 0.01		< 0.01		< 0.01
Sensitivity		0.92		0.44		1		0.92		0.88		0.84
Specificity		0.74		0.88		0.67		0.89		0.82		0.89
PPV		0.34		0.36		0.31		0.56		0.42		0.54
NPV		0.98		0.91		1		0.99		0.98		0.97

EGV: Esophagogastric varices; HCC: Hepatocellular carcinoma; PPV: Positive predictive value; NPV: Negative predictive value; M2BPGi: Mac2-binding protein glycosylation isomer; FAST: FibroScan-AST; FIB-4: Fibrosis-4; LSM: Liver stiffness measurement.

Table 4 The prevalence of esophagogastric varices in Baveno VI criteria and its derivatives

	Baveno VI		Exp. Baveno VI		New NASH C.C
	LSM	platelet	LSM	platelet	LSM	platelet
	< 20	150 <	< 25	110 <	< 30	110 <
EGV/rule in (n)	12/26		8/13		6/9
EGV/rule out (n)	13/165		17/178		19/182

Exp. Baveno VI: Expanded Baveno VI; New NASH C.C: New NASH cirrhosis criteria; LSM: Liver stiffness measurement (KPa); Platelet count (×10⁹/L); EVG: Esophagogastric varix.